Brains of Alzheimer's disease (AD) patients are characterized in part by the formation of high
molecular weight aggregates of amyloid-ß (Aß) peptides, which interfere with neuronal …

Glutaminyl cyclase (QC) was discovered recently as the enzyme catalyzing the
pyroglutamate (pGlu or pE) modification of N-terminally truncated Alzheimer's disease (AD) …

A major neuropathological hallmark of Alzheimer's disease (AD) is the deposition of
aggregated β amyloid (Aβ) peptide in the senile plaques. Aβ is a peptide of 38–43 amino …

N-truncated and N-modified forms of amyloid-β (Aβ) peptide are found in diffused and dense
core plaques in Alzheimer's disease (AD) brain. Among them, the most abundant N …

In the hippocampal formation of Alzheimer's disease (AD) patients, both focal and diffuse
deposits of Aβ peptides appear in a subregion-and layer-specific manner. Recently …

Background Pyroglutamylation of truncated Aβ peptides, which is catalysed by enzyme
glutaminyl cyclase (QC), generates pE-Aβ species with enhanced aggregation propensities …

Modified amyloid β (Aβ) peptides represent major constituents of the amyloid deposits in
Alzheimer's disease and Down's syndrome. In particular, N‐terminal pyroglutamate (pGlu) …

Pyroglutamate-modified Aβ (AβpE3–42) peptides are gaining considerable attention as
potential key players in the pathology of Alzheimer disease (AD) due to their abundance in …

Background Posttranslational modifications of beta amyloid (Aβ) have been shown to affect
its biophysical and neurophysiological properties. One of these modifications is N-terminal …

Glutaminyl cyclase (QC) converts N-terminal glutaminyl residues into pyroglutamate (pE),
thereby stabilizing these peptides/proteins. Recently, we demonstrated that QC also plays a …